← All trials
NCT05387499
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 10, 2022
- Primary completion
- Nov 15, 2022
- Completion date
- Jan 30, 2023
- First posted
- May 24, 2022
- Last posted
- Sep 28, 2022
- Enrollment
- 64
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Nexel Co., Ltd.Lead sponsor
- NovotechCollaborator
- CMAX Clinical ResearchOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.